Markets:

Overview

News

Currencies

International

Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

31.73 -17.27 (-35.24%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Maze Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

Today 16:00 EDT

Via Chartmill

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% ↗

Today 15:01 EDT

This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.

Via The Motley Fool

Topics Regulatory Compliance

Wednesday's session: top gainers and losers ↗

Today 13:30 EDT

Via Chartmill

Which stocks are gapping on Wednesday? ↗

Today 11:30 EDT

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

Today 9:30 EDT

Via Chartmill

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Today 7:00 EDT

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Today 7:00 EDT

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears ↗

March 21, 2026

This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings report.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

February 25, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗

February 18, 2026

a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise...

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge ↗

February 16, 2026

Maze Therapeutics has been flourishing as a stock and in its operations, which is one of the reasons its Chief Medical Officer's recent share sale shouldn't raise concerns for investors.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock ↗

February 01, 2026

Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical...

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗

January 07, 2026

This clinical-stage biotech focused on precision medicines reported significant insider selling, according to recent SEC filings.

Via The Motley Fool

Topics Regulatory Compliance

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Topics Regulatory Compliance

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

November 06, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

November 06, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

November 04, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

October 06, 2025

Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotech

From Maze Therapeutics, Inc.

Via GlobeNewswire

Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗

September 17, 2025

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

Via MarketBeat

What's going on in today's session ↗

September 11, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗

September 11, 2025

Maze's MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and no serious side effects.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 11, 2025

Via Benzinga

Which stocks are moving on Thursday? ↗

September 11, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday ↗

September 11, 2025

Via Benzinga

Thursday's session: gap up and gap down stocks ↗

September 11, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results ↗

September 11, 2025

Shares catapulted Thursday after its experimental treatment for a rare, genetic disease blew past expectations.

Via Investor's Business Daily

Discover the top movers in Thursday's pre-market session. ↗

September 11, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 11, 2025

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.